From a release by another company in 2020 "To date, 12 out of 25 PRVs received for pediatric indications have been sold for a cumulative sale price of USD 1.6 billion" So now KZA has 2 PRV's worth circa USD$260m for a company with a market cap of AUD$86m. Numbers look good to me. The only reason you wouldn't trade them is if you believe they're better used to bring the drugs to market faster.
- Forums
- ASX - By Stock
- Ann: FDA grants RPDD to paxaliaib for AT/RT
From a release by another company in 2020 "To date, 12 out of 25...
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online